Institut Bergonié

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Established: 1923-01-01

Employees: -

Market Cap: -

Website: http://www.bergonie.org

Clinical Trials

Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms

Completed

Conditions: Upper Gingival Squamous Cell Carcinoma

Interventions: Other: Blood sample for identifying the polymorphism

First Posted Date: 2013-04-10

Last Posted Date: 2013-04-10

Lead Sponsor: Institut Bergonié

Target Recruit Count: 121

Registration Number: NCT01827956

Locations: 🇫🇷
Institut Bergonié, Bordeaux, Aquitaine, France

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response

Phase 3

Terminated

Conditions: Leukemia, Myeloid, Chronic-Phase

Interventions: Drug: Imatinib Mesylate 600 MG Oral Tablet
Drug: Imatinib Mesylate 400 MG Oral Tablet
Drug: Imatinib Mesylate

First Posted Date: 2013-04-10

Last Posted Date: 2020-12-31

Lead Sponsor: Institut Bergonié

Target Recruit Count: 68

Registration Number: NCT01827930

Locations: 🇫🇷
Institut Bergonié, Bordeaux, Aquitaine, France

Evolution Natriuretic Peptide Concentrations of B-type (BNP) During General Anesthesia Under Propofol and Sevoflurane Association in Patients Previously Sensitized to Anthracyclines

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Peptide Natriurétique de type B

First Posted Date: 2012-12-21

Last Posted Date: 2015-11-26

Lead Sponsor: Institut Bergonié

Target Recruit Count: 56

Registration Number: NCT01754597

Locations: 🇫🇷
Institut Bergonié, Bordeaux, Aquitaine, France

Validation of a Screening Tool in Geriatric Oncology

Not Applicable

Completed

Conditions: Head and Neck Cancer
Lymphoma
Prostate Cancer
Colorectal Cancer
Breast Cancer
Lung Cancer

Interventions: Other: Geriatric screening tests
Other: Multidimensional geriatric assessment

First Posted Date: 2009-08-24

Last Posted Date: 2021-04-05

Lead Sponsor: Institut Bergonié

Target Recruit Count: 1674

Registration Number: NCT00963911

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France

Efavirenz in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: efavirenz

First Posted Date: 2009-08-24

Last Posted Date: 2022-05-16

Lead Sponsor: Institut Bergonié

Target Recruit Count: 61

Registration Number: NCT00964002

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Conditions: Pancreatic Cancer

First Posted Date: 2009-08-24

Last Posted Date: 2010-04-07

Lead Sponsor: Institut Bergonié

Target Recruit Count: 72

Registration Number: NCT00964171

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France

Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: pegfilgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: prednisone
Drug: liposome-encapsulated doxorubicin citrate
Drug: vincristine sulfate

First Posted Date: 2009-06-01

Last Posted Date: 2022-06-14

Lead Sponsor: Institut Bergonié

Target Recruit Count: 67

Registration Number: NCT00911183

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France

Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: anastrozole
Drug: fulvestrant

First Posted Date: 2009-03-30

Last Posted Date: 2021-02-24

Lead Sponsor: Institut Bergonié

Target Recruit Count: 120

Registration Number: NCT00871858

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France

Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer

Phase 2

Terminated

Conditions: Primary Peritoneal Cavity Cancer
Colorectal Cancer

Interventions: Biological: cetuximab
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Procedure: adjuvant therapy
Procedure: therapeutic conventional surgery

First Posted Date: 2008-10-03

Last Posted Date: 2021-01-26

Lead Sponsor: Institut Bergonié

Target Recruit Count: 18

Registration Number: NCT00766142

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France

Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer

Phase 2

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Metastatic Cancer
Pain

Interventions: Drug: Acetaminophen
Drug: Morphine Sulfate
Other: Questionnaire administration
Procedure: Quality-of-life assessment
Procedure: Radiofrequency ablation

First Posted Date: 2008-07-10

Last Posted Date: 2021-03-26

Lead Sponsor: Institut Bergonié

Target Recruit Count: 78

Registration Number: NCT00712712

Locations: 🇫🇷
Institute Bergonié, Bordeaux, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy